The tenth anniversary of the Kigali Amendment marks a pivotal moment for the inhalation industry.
As the transition away from HFC propellants accelerates, achieving equivalent clinical performance with low global warming potential (GWP) alternatives demands a detailed understanding of their distinct physicochemical properties, and precise, system-level design interventions to match.
In our latest article for ONdrugDelivery, Tony Mallett, Platform Development Group Manager, and Thomas Daly, Development Engineer, explore how Bespak is optimising pressurised Metered Dose Inhaler (pMDI) valves, actuators, and manufacturing processes for next-generation propellants.
Their work spans elastomer compatibility and actuator geometry through to CFD-modelled refill dynamics and lifecycle assessment of the BK357 valve platform.
Read the full article below.
